Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering.

Citius Pharmaceuticals, Inc. declined 1.34% in after-hours trading, following the announcement by its majority-owned subsidiary, Citius Oncology, of a public offering of 6,818,182 shares of common stock and warrants at $1.32 per share. The offering, which includes warrants exercisable at $1.32 per share and expiring five years from issuance, may have led to the stock's decline as investors reacted to the potential dilution of existing shares.